Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis
Key facts
- Where
- Danderyd, Gothenburg, Halmstad, Höllviken, Kristianstad, Linkoping, Nykoping, Stockholm és Uppsala, SvédországSee the 10 sites
- Phase
- 2. fázis
Where in Svédország
- Hudläkargruppen Mörby CentrumDanderyd, SvédországTaking people
- Vasakliniken HudläkargruppGothenburg, SvédországTaking people
- HudcenterHalmstad, SvédországTaking people
- Doctor RY Skin ClinicHöllviken, SvédországTaking people
- Hudläkarna NordöstKristianstad, SvédországTaking people
- Cordinator Medical Service ABLinkoping, SvédországTaking people
- Region SoermlandNykoping, SvédországTaking people
- Region Stockholm – SLSOStockholm, SvédországTaking people
- Region UppsalaUppsala, SvédországTaking people
- Uppsala University HospitalUppsala, SvédországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Galenica AB
- Trial code
- EU 2025-521620-29-01
- Record updated
- 2026. október 28.
- Original description
To demonstrate superiority in time to relapse of eczema with moisturisers Oviderm cream and Urea/propylene glycol cream, respectively, as compared to non-treatmentRead full original descriptionShow less
Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis compared to no treatment: A prospective, controlled, split-body study
To demonstrate superiority in time to relapse of eczema with moisturisers Oviderm cream and Urea/propylene glycol cream, respectively, as compared to non-treatment
Inclusion: The patient has given their written consent to participate in the study; Age ≥ 18 years; Patients with known AD or diagnosed with AD according to the Williams criteria [1] with visible atopic lesions on arms and/or legs. Two lesions on left respective right side with a size of 2 x 2 cm to 10 x 10 cm should be available, i.e., study areas. The largest lesion should not be more than 50% larger than the smallest lesion in length and width, i.e., the length of the largest selected lesion ≤ 1.5× the length of the smallest and the width of the largest selected lesion ≤ 1.5× width of the smallest lesion; Moderate to severe form of AD, IGA ≥ 3 [2], a mEASI score on the defined study areas of ≥ 4 and with a difference between left study area to right study area of ≤ 1 and which, in the opinion of the Investigator, can achieve complete clearance with a class III corticosteroid treatment for approximately 4 weeks.
Exclusion: Patients treated for AD with systemic drugs, topical corticosteroids class IV and light treatment during the last 3 months; Any concomitant medications that, in the opinion of the Investigator, could affect the study outcome; Known sensitivity or allergy to any of the study products; Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (e.g., compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments or procedures; Eczema exclusively on the hands; Patients assessed by the Investigator to have mild atopic dermatitis; Patients assessed by the Investigator to have poor compliance; Patients assessed by the Investigator to have difficulty reading and understanding the local language; Patients who are pregnant, breast feeding or planning to become pregnant during study participation.